Osteogenic inhibition in multiple myeloma

Cell Journal

Volumn 15, Issue 3, 2013, Pages 266-271

  Habibi, Hussain ^a   Abroun, Saeid ^a   Hajifathali, Abbas ^a   Soleimani, Masoud ^a   Kavyani, Saeid ^a   Kalantari, Nasim ^a   Eslahchi, Susan ^b  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cord blood stem cells; Multiple myeloma; Osteoblast; Sclerostin; SOST

Indexed keywords

MESSENGER RNA;

ARTICLE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; ILIAC CREST; MULTIPLE MYELOMA; MYELOMA CELL; OSTEOBLAST; RNA EXTRACTION;

EID: 84883348503     PISSN: 22285806     EISSN: 22285814     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Basak GW, Srivastava AS, Malhotra R, Carrier E. Multiple myeloma bone marrow niche. Curr Pharm Biotechnol. 2009; 10(3): 345-346.
2. Kyle RA, Rajkumar SV. Multiple myeloma.Blood. 2008; 111(6): 2962-2972.
3. Sezer O. Myeloma bone disease: recent advances in biology, diagnosis, and treatment. Oncologist. 2009; 14(3): 276-283.
4. Cook R. Introduction: multiple myeloma. J Manag Care Pharm. 2008; 14(7): 4-6.
5. Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood. 2006; 108(13): 3992-3996.
6. Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol. 2005; 16(8): 1223-1231.
7. Heider U, Fleissner C, Zavrski I, Kaiser M, Hecht M, Jakob, et al. Bone markers in multiple myeloma. Eur J Cancer. 2006; 42(11): 1544-1553.
8. Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Donofrio G, Bonomini S, et al. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res. 2007; 67(16): 7665-7674.
9. Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S, et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood. 2005; 106(7): 2472-2483.
10. Hoeppner LH, Secreto FJ, Westendorf JJ. Wnt signaling as a therapeutic target for bone diseases. Expert OpinTher Targets. 2009; 13(4): 485-96.
11. Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV, Komm BS, et al. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem. 2005; 280(39): 33132-33140.
12. Rao TP, Kuhl M. An updated overview on Wnt signaling pathways: a prelude for more. Circ Res. 2010; 106(12): 1798-1806.
13. Balemans W, Van Hul W. Human genetics of SOST. J Musculoskelet Neuronal Interact. 2006; 6(4): 355-356.
14. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, DAgostin, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008; 23(6): 860-869.
15. Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, et al. Genomic deletion of a long-range bone enhancer misregulatessclerostin in Van Buchem disease. Genome Res. 2005; 15(7): 928-935.
16. Balemans W, Van Hul W. Identification of the disease-causing gene in sclerosteosis-discovery of a novel bone anabolic target? J Musculoskelet Neuronal Interact. 2004; 4(2): 139-42.
17. Terpos E, Sezer O, Croucher P, Dimopoulos MA. Myeloma bone disease and proteasome inhibition therapies. Blood. 2007; 110(4): 1098-1104.
18. Ehrlich LA, Chung HY, Ghobrial I, Choi SJ, Morandi F, Colla S, et al. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood. 2005; 106(4): 1407-1414.
19. Lee JW, Chung HY, Ehrlich LA, Jelinek DF, Callander NS, Roodman GD, et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood. 2004; 103(6): 2308-2315.
20. Goodwin HS, Bicknese AR, Chien SN, Bogucki BD, Quinn CO, Wall DA. Multilineage differentiation activity by cells isolated from umbilical cord blood: expression of bone, fat, and neural markers. Biol Blood Marrow Transplant. 2001; 7(11): 581-588.
21. Sila-Asna M, Bunyaratvej A, Maeda S, Kitaguchi H, Bu-nyaratavej N. Osteoblast differentiation and bone formation gene expression in strontium-inducing bone marrow mesenchymal stem cell. Kobe J Med Sci. 2007; 53(1-2): 25-35.
22. Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene. 2004; 341: 19-39.
23. Roodman GD. Pathogenesis of myeloma bone disease. J Cell Biochem. 2010; 109(2): 283-91.
24. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest. 2006; 116(5): 1202-1209.
25. Ducy P. Cbfa1: a molecular switch in osteoblast biology. Dev Dyn. 2000; 219(4): 461-471.
26. Colucci S, Brunetti G, Oranger A, Mori G, Sardone F, Specchia G, et al. Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer Journal. 2011; 1(6): e27.
27. Hamersma H, Gardner J, Beighton P. The natural history of scle-rosteosis. Clin Genet. 2003; 63(3): 192-197.